Skip to Main Content

Hope S. Rugo

MD

Breast oncologist

Dr. Hope Rugo is a hematologist-oncologist who specializes in breast cancer treatment. She joined the UCSF Carol Franc Buck Breast Care Center after a decade at UCSF Medical Center, where she worked in bone marrow transplantation for a variety of diseases, including breast cancer.

Rugo is co-director of UCSF's breast cancer clinical trials program. She is the principal investigator for several clinical trials of potential new therapies. She is also an investigator with the Bay Area's SPORE (Specialized Programs of Research Excellence) on breast cancer. The National Cancer Institute established SPORE to foster collaborative, interdisciplinary cancer research.

  • Education

    University of Pennsylvania School of Medicine, 1984

  • Residencies

    UCSF Medical Center, Internal Medicine, 1987

  • Fellowships

    UCSF Medical Center, Hematology, 1990

    UCSF Medical Center, Oncology, 1995

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Professor

  • Languages

    French

    Spanish

Where I see patients (1)

    My reviews

    4.9

    Overall Experience
    311 Ratings
    Explained things in a way that was easy to understand
    309 Ratings
    Did the doctor pay attention to your concerns
    307 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    301 Ratings
    Knew the important information about your medical history
    307 Ratings
    The provider showed respect for what you had to say
    310 Ratings
    The provider spent enough time with me
    310 Ratings
    Decorative Caduceus

    T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk H...

    A Kaplan-Meier method will be used to estimate the survival curves and a stratified log-rank test will be used to compare the invasive disease-free survival (iDFS) of the two arms. A stratified Cox model will be used to estimate t...

    Recruiting

    Decorative Caduceus

    Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo...

    The outcome measure of the study is IDFS, defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of first invasive disease recurrence (local, regional or distant), the date of se...

    Recruiting

    Decorative Caduceus

    The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanc...

    Progression Free Survival is defined from the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST 1.1 or death from any cause, whichever occurs first.

    Recruiting

    Decorative Caduceus

    Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Br...

    Progression-Free Survival (PFS) is defined as the time from the first dose of study treatment to the date of disease progression as assessed by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death due to any cause, ...

    Recruiting

    Decorative Caduceus

    A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positiv...

    Recruiting

    Decorative Caduceus

    Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients...

    BORR is defined as the percentage of patients achieving complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and will be reported for each arm along with 95% two-side...

    Recruiting

    Decorative Caduceus

    A Safety Study of SGN-LIV1A in Breast Cancer Patients

    An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

    Recruiting

    Decorative Caduceus

    DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small ...

    Maximum Tolerated Dose (MTD) or recommended dose expansion (RDE) of DS-8201a (Part1) are based on the occurrence of DLTs.

    Recruiting

    Decorative Caduceus

    Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Ca...

    The primary endpoint for the study is the median radiographic progression free survival (rPFS) in the Enobosarm Treatment Group compared to the Control Treatment Group. Progression will be defined based on RECIST 1.1.

    Recruiting

    Decorative Caduceus

    A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial C...

    Number of Participants with DLTs and DLT-Equivalent Toxicities

    Recruiting

    Share